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Abstract 
For centuries, pharmacognosy was essential for the identification, quality, purity and – until 
the end of the 18th century even for the efficacy – of medicinal plants. Since the 19th centu-
ry, it concentrated on authenticity, purity, quality and the analysis of active substances, was 
established as an academic branch discipline within pharmacy and continuously developed 
into a modern, highly sophisticated science. Even though the paradigm in pharmacy changed 
in the 19th century with the discovery of morphine and concentrated on single substances 
which could be synthesized fast by the upcoming industry, medicinal plants always remained 
an important element of the Materia medica and during the last decades medicinal plants con-
tinue to be both a sources of remedies and natural products are an inspiration for new medi-
cine. In this research, pharmacognostic skills remain an essential element, both with regards 
to identity, quality assurance of botanicals (both herbal medicines and supplements) and the 
discovery and development of new medicines. Over the years the specific pharmacognostical 
tools have changed dramatically, and most recently DNA-based techniques have become an-
other element of our spectrum of scientific methods 
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Introduction 
Pharmacognosy has accompanied humans for millennia and over centuries developed tradi-
tions of evidence-based knowledge in cultures. It addresses both challenges relating  to the 
supply of safe medicines and offers unique opportunities for modern drug discovery. – The 
term will be used throughout the paper in the literal sense “the knowledge about medicinal 
drugs” and is not reduced to the definition of the academic discipline since the 19th century.  
In this paper, we mainly focus on the history of pharmacognosy in Europe being well aware 
of the fact that principally similar developments can be observed in many regions and cul-
tures in the world which – metaphorically spoken – open unlimited horizons for research in 
pharmacognosy and drug discovery. Until the early 19th century, the regnum vegetabile or 
kingdom of plants was the most important and uncontested source for therapeutic agents in 
medicine and pharmacy.  
As keeping and restoring health is doubtlessly an essential element of survival, it is not sur-
prising that the knowledge about medicinal plants was highly appreciated as the famous bot-
anist Augustin-Pyrame de Candolle (1778–1841) who stated: “Among all kinds of human 
knowledge, pharmacognosy is the most useful” and in 1909 the celebrate pharmacognosist 
Alexander Tschirch (1856–1939) considered it “eine wahre scientia regia”, a real royal sci-
ence [1]. Yet, the ideas about the character, definition and purpose of pharmacognosy 
changed over the centuries. While it comprised any knowledge about medicinal plants like 
identity, origin, habitat, morphology, medicinal properties, ways of application, methods of 
preparation, and adulterations from ancient times on, in the context of the differentiation of 
sciences since early modern time, it gradually developed into a science which mainly concen-
trated on identity, quality and purity. Since early modern age, one of the traditionally central 
parts of what later would be called pharmacognosy– the efficacy of medicinal plants which 
was always defined by the referring contemporary theoretical concepts like the Galenic hu-
moral pathology – shifted into pharmacology. However, it has always remained a complex, 
ambitious science comprising various expertise in many other scientific disciplines and today 
contributes again significantly to the exploration of the effects and efficacy of medicinal 
plants.  
With the development of the plant chemistry since the 18th century culminating in the isola-
tion of morphine by the German apothecary Friedrich Wilhelm Adam Sertürner (1783–1841), 
the attention of pharmacy and medicine finally turned to single substances, their derivatives 
and synthetic molecules which could be produced fast on an industrial level and were thought 
to be better controllable in dosage, efficacy and side effects. In the progress of this develop-
ment, many medicinal plants fell into oblivion, were not further investigated or not even stud-
ied at all [2, 3, 4].  
Yet, medicinal plants and the knowledge about their identity, quality, purity and efficacy 
have always remained an important element of medicine and pharmacy. There can be no 
doubt that M. Wichtl’s Herbal Drugs and Phytomedicines. A Handbook for Practise on a Sci-
entific Basis [German ‘Teedrogen und Phytopharmaka’ with the 6th edition published in 
2016, Blascheck et al. 5]) remains a core resource for the identification of herbal materials. It 
is unique and a true representation of traditional pharmacognosy in its best sense. It high-
lights the morphological and some basic phytochemical characteristics of important botanical 
drugs. At the same time, it is an area which has received little attention and in the 21st centu-
ry few pharmaceutical scientists are trained in this field. As the name indicates it is a prac-
tice-centred book and does not strive for incorporating the latest methodological innovations, 
but for practical usefulness. As another researcher in the field famously stated “Jeder 
Fortschritt in den Methoden ist auch ein Fortschritt in der Wissenschaft” (Egon Stahl: ‘Every 
progress in methods also is a progress in science’), over the last two hundred years the ap-
proaches and methods in this field have changed dramatically and continue to do so [6]. 
There have been numerous reviews assessing specific developments in this field of research 
[e.g. 7, 8,9], which has also been covered in a wide range of textbooks [e.g. 10- Trease and 
Evan’s Pharmacognosy,11; 7; 12, as well as, for example, German language textbook like 13, 
14]. 
During the last decades, the scientific interest has turned again to medicinal plants as research 
in tradition, compounds and composition might reveal new opportunities for the future chal-
lenges and essential medical needs, not only under the aspect of “soft therapeutics” but also 
as a source of highly effective resources for the treatment of serious diseases with presently 
unsatisfying therapeutic solutions. Today we have new methods and much more knowledge 
to explore the composition of plants under the aspect of their efficacy much deeper than ever 
and can now link this to pharmacological and clinical studies allowing a much better under-
standing of herbal medicines. In this development, pharmacognosy will be a central and irre-
placeable science and cover further essential fields of investigation. 
 
Millennia of experience and tradition - The Scientia Regia 
The knowledge about the identity, quality, properties and uses of medicinal developed over 
thousands of years in a process of evidence-based experience, exchange of expertise and the 
forming of a complex tradition which nowadays can be explored by the methods and instru-
ments of modern science. 
While ancient cultures around the globe had gathered, and adopted knowledge about the heal-
ing properties of medicinal plants and handed it down – enriched by further developing 
knowledge and evidence-based experience – from generation to generation, in Europe it was 
the famous work De materia medica written by the Greek physician Dioscorides (1st c.) 
which probably became the most influential work for forming and transmitting pharmacog-
nostic knowledge. Dioscorides is said to have been a physician of the Roman army accompa-
nying them during their conquest campaigns around the Mediterranean regions and by this 
exploring the medicinal potency of the local florae. He recorded more than 800 plants and 
their products giving information about their vernacular names, provenance, morphology, 
medical properties, and medical-pharmaceutical applicability. He even mentioned criteria to 
differentiate between the genuine drugs and potential adulterations. For the systematic 
presentation, the completeness of knowledge and the evidence-based information, for more 
than 1500 year this work determined the perception and concept of pharmacognosy in Eu-
rope. In the following centuries, it appeared in innumerable editions and adapted versions, 
among them the famous Anicia Juliana Codex or Vienna Dioscorides (512 AD) which is il-
lustrated by sophisticated depictions of plants and today is kept in the Austrian National Li-
brary under the signature Cod. med. gr.1. The impressive illustrations of this codex reveal the 
high book art and admirable book illustration in the Byzantine period. The codex became a 
model for numerous herbals of the middle age and the beginning early modern time [15,16]. 
Many medicinal plants of Disocorides` work De materia medica are still today important 
therapeutics of our Materia medica [17, 51] 
The European tradition, however, was also influenced by continuous intercultural exchange 
via the great trade routes, travel and commerce. Origins of such knowledge were for example, 
for example, the Ayurvedic body of knowledge containing the ancient and complex Indian 
system of medicine represented by famous works like the Carakasaṃhitā (1st c. BC-2nd c. 
AD) and the Suśrutasaṃhitā (early 3rd to early 6th c.), which comprise explanations of hun-
dreds of medicinal plants and their application. In China, the so-called Pen-tʼsao literature 
reflected centuries of experience and tradition in the application of medicinal plants. The 
work Shen-nungʼs Pen-Ts’ao ching (Shen-nungʼs classics on pharmaceutics, anonymous, 
later Han dynasty 23/25-220 AD) offered information and comments on more than 300 me-
dicinal plants used in the classic Chinese medicine [18, 19]. 
From the late 7th century onward, Arabic-Islamic scholars played an essential role as inter-
mediaries in the transfer of knowledge between the classic antiquity and Latin Europe. High-
ly interested in science and exploration, these Arabic scholars started to translate the extant 
original Greek works but also translations in other languages like Syrian into Arabic and, 
consequently, provided a solid fundament for further scientific development. However, such 
activities were far from being plain translations and copying, but the Arabic-Islamic scholars 
enriched the classical pharmacognostic knowledge with traditional and local empirical 
knowledge, own ideas and expertise from experience. At the same time, the Arabs maintained 
intense trade relations and were connected to the contemporary great trade routes like the Silk 
Road and the Incense Road. In addition, the Arabic empire expanded widely to the Middle 
East, North Africa and to Western Europe, mainly the Iberian Peninsula which lead into an 
intense contact with different cultures and a mutual participation in expertise. Through these 
routes medicinal plants, for example, from the Indo-Iranian, Syrian, Afghan, the Chinese and 
Indian tradition including information about medicinal indications and applications were in-
tegrated into the Arabian materia medica. Similarly, medicinal plants from the Iberian Penin-
sula made an important contribution to the further formation of medieval pharmacognostic 
knowledge. The scientific potential of the pharmacognosy during the medieval Arabic-
Islamic period is reflected in the  general medical literature containing comprehensive infor-
mation about the characteristics and use of medicinal plants such as the works by Rhazes 
(865-925), Ibn Sina (980-1037) also known as Avicenna, and Ibn al-Ğazzar (died ap-
prox.1004) or explicitly pharmacognostic works, for example, the Kitāb al-Ŷāmi` li-mufradāt 
al-adwiya wa-l-agdiya written by Ibn al-Baytâr (around 1190–1248), the Kitāb al-adwiya al-
mufrada by Ibn Wāfid (999-app.1068) and the Kitāb fī l-adwiya al-mufrada by Al-Ghâfiqî 
(died 1165). This comprehensive medical and pharmacognostic lore was delivered to Europe 
by Latin translations and formed the fundament for the further development of pharmacogno-
sy in Europe [4, 20, 21, 22]. 
In the process of forming pharmacognostic knowledge in Latin Europe, the ancient lines of 
tradition merged with European lines of transmitting knowledge such as the monastic phar-
macy, the tradition of the School of Salerno and popular expertise represented by works like 
the Macer floridus (between 1080 and 1100) probably written by the cleric Odo von Meung, 
the Circa instans and the Gart der gesuntheit (1485) by Johann Wonnecke von der Kaub 
(1430-1503/04). This corpus of medieval pharmacognostic expertise formed the foundation 
for the further development of knowledge about the properties of medicinal plants in Europe 
[16, 23]. 
In the early modern period (16th-17th century), the great herbals presented and transmitted 
the pharmacobotanical knowledge like the Kreütterbuch (1539) by Hieronymus Bock (1498-
1554), the various editions of the Kreutterbuch by Pietro Andrea Mattioli (1501-1577) the 
different editions of the Neuw vollkommentlich Kreuterbuch by Tabernaemontanus (1525-
1590). In the context of the European expansion, new exotic drugs were brought to Europe 
and the pharmacognostic knowledge about these medicinal plants was integrated into the de-
velopment of the European traditions [52]. Pharmacognostic expertise became even more 
essential to identify drugs, their origin, their efficacy, purity and their adulterations. Special 
works about the Materia medica and pharmacopoeias reflect the contemporary difficulties 
and efforts to guarantee these basic requirements. 
While the differentiation and formation of modern sciences started in early modern time, in 
the academic curriculum in the 16th century, pharmacognosy as actually one of the oldest 
sciences remained initially a plain subject at the Faculty of Medicine first taught as Lectura 
simplicum (lecture about the simples) accompanied by the Ostensio simplicium (presentation 
of the simples), and afterwards as Materia medica (lecture about medicinal drugs) [1]. Only 
in the 18th century, pharmacognosy started to develop into a defined academic branch disci-
pline in pharmacy.  
While physicians, botanists and pharmacists like Johann Adam Schmidt (1759-1809), who is 
credited with defining the term in his posthumously published work Lehrbuch der Materia 
Medica (1811), Theodor Wilhelm Christian Martius (1796-1863), and Matthias Schleiden  
1804-1881) paved the way for the differentiation of pharmacognosy into an academic disci-
pline, it was the Swiss apothecary Friedrich August Flückiger (1828-1894) and finally the 
famous German apothecary Alexander Tschirch (1856-1939) who at the turn to the 20th cen-
tury perfected the definition and perception of pharmacognosy [24]. Tschirch explained 
pharmacognosy as a universal synopsis of the medicinal drug considering any type of 
knowledge necessary for identification and characterization, except the physiological efficacy 
and defined special disciplines which he considered to be essential for forming such compre-
hensive knowledge: Pharmakoërgasie (cultivation, harvesting, processing of harvested mate-
rial), Pharmakoëmporia (trade routes, export and import ports, processing of drugs in the 
import ports), Pharmakodiakosmie (traded varieties, packaging), Pharmakobotanik (botany, 
systematics, morphology, anatomy, physiology, pathology), Pharmakozoologie (zoology, 
systematics, morphology, anatomy, physiology, pathology), Pharmakochemie (chemistry of 
drugs), Pharmakophysik (physics of drugs), Pharmakogeografie (geography of drugs), 
Pharmakohistoria (history of drugs), Pharmakoethnologie (ethnology of drugs) und der 
Pharmakoetymologie (etymology of drug names) [1]. While Tschirchʼs predecessors already 
had emphasized the multidisciplinary character of pharmacognosy, Tschirch went a step fur-
ther and stated that the main chemical compounds determined the nature and medical proper-
ties of medicinal drugs and therefore built the connection between the drugs to characterize 
them accordingly, e.g. as saponine- drugs, alkaloid-, and anthraquinone-containing drugs. 
Defining medicinal drugs for the first time by their chemical compounds, Tschirch paved the 
way for pharmacognosy as a modern science and developed the “knowledge of drugs 
(Drogenkunde) into a science of drugs (Drogenwissenschaft)” [1, 24, 25]. In this context, 
Tschirch postulated that the pharmacochemistry had to explore all compounds of a drug as 
“the efficacy of a drugs is rarely caused by only one compound but mostly by the composi-
tion of the compounds” [Die Pharmakochemie (muss) „das Ensemble möglichst aller Be-
standteile kennen lehren, denn die Wirkung der Droge ist nur selten das Korrelat eines Be-
standteils, und meist eine Mischwirkung.“]. This opinion obviously did not follow the con-
temporary scientific mainstream which considered single compounds to be the best therapeu-
tic solutions.  
However, Alexander Tschirch’s impressive achievements and innovative research approaches 
did not lead to intense research efforts in exploring the properties and potential therapeutic 
use of medicinal plants even though pharmacognosy was well established in the academic 
curriculum of the pharmaceutical branch disciplines in many countries – with the exception 
of Germany, a fact which was often criticized and discussed [24, 46]. 
It took decades until his concept of exploring the chemical compounds was intensely devel-
oped by researchers like Kurt Mothes (1900–1983) in Halle, Germany, who included plant 
physiology, biochemistry, isotope technology and biosynthesis into his research program and 
Richard Wasicky (1884–1970) who is a representative for the scientific pharmacognosy in 
Austria [24, 26, 27]. 
There is ample historical  evidence that the concentration on the application of single sub-
stance in drug discovery and development pushed plants as multi-compound mixtures into the 
background. This was driven by the expectation that this made it easier to  control dosage and 
efficacy and, most importantly, that such medicines could be produced in large amounts at a 
low price in the growing pharmaceutical and chemical industry to satisfy the needs. This is 
exemplified by  highly effective substances like the Camptothecin derivatives from Camp-
totheca acuminata Decne., the vinca alkaloids from Catharanthus roseus (L.) G. Don, or tax-
anes from Taxus brevifolia Nutt. 
The challenges of investigating the complexity of the composition, the efficacy, synergistic 
effects and the adequate dosages could not be met by the analytical-technical tools of the pe-
riod. Neither did the state of knowledge in related sciences like biochemistry, pharmacology, 
biotechnology and genetics  research allow a fruitful research on such complex mistures.  
With the large number of unsatisfied needs and future challenges in medical therapy, plants 
as multi-compound mixtures have gained new attention as potential therapeutic agents. With 
the  immense knowledge in many scientific fields accompanied by adequate analytical-
technical approaches offers unique possibilities to explore the medicinal plants which have 
been used over centuries again based on empirical evidence and make them available inmod-
ern therapies. This requires – as outlined in the following part - more detailed studies in ana-
lytics, efficacy, synergistic efficacts and clinical application are necessary and it is also essen-
tial to reconsider the present regulatory framework and its applicability for the registration of 
phytotherapeutics and plant-based medicines 
 
Pharmacognosy today – analytical and regulatory challenges 
This focus on complex mixtures remains a core interest of modern pharmacognosy, and in a 
very general way it can be divided into two lines of activities, thus expanding and modifying 
the original focus (see above): 
- The identification and authentication of drug substances and the quality of the result-
ing medicines and the 
- Search for new medicines, their production and research into understanding their 
pharmacological (incl. toxicological) effects and their effectiveness.  
Clearly the first very much follows the classical definitions as laid out above. These aspects 
of the field were developed at a moment in history when complex preparations derived from 
natural sources still were the only source of medicines. Today, a very diverse set of pharma-
cognostic methods is available, including microscopic [6], phytochemical [28] and genetic 
[29] techniques. Here is not the space for specifically reviewing such techniques, but to high-
light these changing approaches, and the importance of the regulatory framework in defining 
best practice. 
With regards to drug substances and their quality and analysis and using Hypericum perfora-
tum L. (St. John’s Wort) as an example, Agapouda et al. [30] reviewed the quality control of 
H. perforatum. The species is one of the most commonly used ones and a large number of 
herbal medical preparations are used and many are licensed or registered, most importantly 
for treating minor or moderate forms of depression and a range of mood disorders. In 2008 a 
Cochrane review evaluated 29 randomised double-blind trials (5489 patients with mild to 
moderately severe depression) found SJW extracts to be superior to placebo, and with similar 
effectiveness to standard anti-depressants, but with fewer side effects [31]. A huge number of 
experimental methods are available with TLC and HPTLC being the basic methods in the 
routine approaches. HPLC-DAD is the most widely applied method for quantitative analysis 
with a high degree of versatility. Near Infrared Spectroscopy is important in industrial prac-
tice. Very sensitive LC-MS-based methods are becoming more important especially in phar-
macokinetic studies. Other approaches, such as DNA barcoding, and NMR metabolomics are 
currently not accepted as validated methods, but offer new opportunities and while they may 
not use the term  ‘pharmacognosy’ these methods all are used with in essence the same objec-
tives as they were defined by Alexander Tschirch and his predecessors – to ascertain the au-
thenticity and quality of the herbal substance and the products derived from it.  
DNA-barcoding is making an important contribution to understanding not only the quality, 
but the systematic complexity of the species and its relatives. DNA barcoding uses small and 
well-defined DNA sequences in the plants’ genome as a distinctive characteristic allowing a 
species’ identification. The methodology was, of course, developed in the context of genetic 
research and in botany plays a key role in plant systematics becoming an important tool not 
only for specimen identification, but also for significant advances in systematics allowing a 
much better understanding of the relationship between taxa. In the last years, it has also been 
embraced as a tool to authenticate botanical drugs at the species level (i.e. it cannot be used to 
identify a botanical drug but only the taxon it is derived from).    
For example, H. perforatum L. has in recent years attracted considerable interest, both from 
the perspective of plant systematics, as well as medicinal plant authentication (i.e. pharma-
cognosy). The taxon has a complex history of recurrent polyploidisation and gene flow be-
tween H. perforatum and H. maculatum Crantz. [32,33]. Morphological and chromosome 
data point to the possibility that H. perforatum L. could be a hybrid of H. attenuatum Fisch. 
ex Choisy and H. maculatum Specifically ITS1 and ITS2 sequence data [34] allowed a clear 
distinction from important related species including H. maculatum, one of the potential parent 
species of the assumed hybrid. While this has allowed great progress in our understanding of 
genus’ systematics, its use in a more regulated environment like the authentication of medici-
nal plants, requires further research and development.  
The first routine methods, which could be used to clearly distinguish the pharmaceutically 
used species from other ones was published in 2017. A general DNA based method was in-
corporated into the British Pharmacopoeia using Ocimum tenuiflorum L. or tulsi as an exam-
ple [35].  
 Clearly it will allow the identification of genetically distinct material in a botanical drug, but 
the limitations of the approach are multi-fold. It is one of many techniques used to define the 
composition and quality of a botanical drug and of extracts derived from it.  Obviously, all 
DNA-based methods also are indirect methods in the sense that they do not allow to identify 
or even quantify the active metabolites in the plant or its preparations. The most important 
limitation clearly is that in general it can only be used on unprocessed drug material and not 
with extracts and after any other process which results in the degradation of the DNA. While 
opportunities for DNA barcoding with processed materials are actively explored (e.g. am-
plicon metabarcoding – AMB), methods which can be incorporated into a pharmacopoeia for 
such materials still will require considerable research and development. The complexity of 
species and the species concept need to be taken into consideration [e.g. in complex species 
(aggregates), especially in taxa where apomixis and polyploidy are common]. Consequently, 
one will always have to rely on a combination of methods. 
In our context it does highlight that all these methods contribute to the cognosis or identifica-
tion of the pharmacon or the drug substance. As pointed out, among others, by Parveen et al 
[29], in general a combination of methods will be needed for the ‘successful authentication of 
botanical ingredients’. There are few drugs for which such a detailed set of analytical tech-
niques is available, and depending on the breadth of definition of a medicinal (and health 
food) plant for thousands and more species there is a need to develop such pharmacognostical 
techniques. Clearly, a limit will have to be drawn and this must be based on the relevance of 
these species in national and international trade networks. 
While in this context pharmacognosy remains essentially an analytical science, it is also em-
bedded in the specific regulatory framework of a country or regions. Lack of quality control 
is common and the resulting problems with adulteration and poor quality have come into the 
focus of discussion. This has been identified in numerous countries including the USA (see 
below), Japan [36] and Europe [37]. Such problems are commonly linked with unregulated or 
poorly (self-)regulated products and very often with so-called lifestyle drugs (anti-aging, 
slimming, aphrodisiacs, e.g. [34]). Since 2011 (St. Gaffner, pers comm, 04/01/2017) in the 
USA three non-profit organisations - the American Botanical Council (ABC), the American 
Herbal Pharmacopoeia (AHP), and the University of Mississippi's National Center for Natu-
ral Products Research (NCNPR) - have been running a large-scale programme on ingredient 
and product adulteration and the associated risk, with the specific goal to engage the relevant 
stakeholders in ascertaining best practice (see  
http://cms.herbalgram.org/BAP/index.html?ts=1475004575&signature=ed71dcf23c2084bba7
8071bddd2a0b38).  
Already at the time of Alexander Tschirch a global trade in botanical materials for medical 
use existed and today this trade has increased incrementally, highlighting the need for a better 
understanding of the global trade networks (value chains) and how these impact both on the 
livelihood of primary producers and the resulting challenges for ascertaining best quality [35, 
38] While there have been tremendous advances in a wide range of analytical techniques in-
cluding hyphenated ones [28, 39], the core methods required in routine quality control must 
be robust, fast, and highly economical (both in terms of time and equipment).  
The above defines a crucial set of pharmacognostical task and while it may not be an area 
which results in highly influential publications, it is essential in setting industrial standards. 
At the same time the fast development of ever more sensitive and advanced techniques offers 
opportunities which are also of relevant in the context of the second major area within phar-
macognosy – the search for new medicines, their production and research into understanding 
their pharmacological (incl. toxicological) effects and their effectiveness [40, see also 41].  
In taking such a wider perspective, numerous other methods come into play, including the 
diverse methods of isolation, pharmacological and clinical investigation as well as the associ-
ated pharmacovigilance schemes. Clearly all were developed well after the initial definition 
of the field of pharmacognosy, which until the second half of 20th century relied on the ob-
servation of effects of preparations when applied to humans and animals. Interestingly, dur-
ing the process of defining the concept pharmacognosy (see above for the work of J.A. 
Schmidt and others) of the 19th century, morphine from (Papaver somniferum L. Papavera-
ceae), had already been identified by Friedrich Wilhelm Sertürner in 1804 and in 1817 was 
chemically characterized as an alkaloid. Over 100 years later, in 1923 in Manchester JM Gul-
land and R Robinson established its full structure. Drug discovery from natural sources con-
tinues to yield exciting new drug leads [8,9] and research is today embedded in complex reg-
ulations of best practice including the recognition of the rights of provider (countries) (Bauer 
et al., forthcoming). Recently, the plant derived natural products galanthamine and Peplin / 
ingenol-3-angelate [42] have become important new medicines. Plant derived anti-cancer 
agents remain core therapeutic options; e.g. [43] and numerous fungal metabolites have been 
developed or are under development [44]. These techniques also lead to the need for the ma-
jor development of bioinformatics and related techniques. One can argue that these areas no 
longer should be included under the heading of pharmacognosy in a strict sense, but even 
then one will have to acknowledge that pharmacognosy is the origin of all these disciplines 
and research activities.  
 
Conclusion 
Today pharmacognosy faces numerous challenges and at the same time offers many opportu-
nities. Identification and authentication of nature derived products have been a continuous 
core challenge and will remain an important competence. Clearly new methods are required 
for this and as such DNA-based techniques are simply an addition to the wide range of tools 
used in this context, and they are an exciting opportunity. Here we wanted to show the con-
ceptual continuum and the constant incorporation of new methods into a medical-
pharmaceutical science. In addition, pharmacognosy nowadays has the unique opportunity to 
explore further fields of investigation, especially in drug discovery and clinical development 
and by this return to its origins of a complex and comprehensive science for both, medicine 
and pharmacy.  
Century-old traditions in all cultures reflect an immense knowledge of medicinal plants use 
which is reflected by innumerable historical sources. This fact has been commonly accepted 
and dealt with in many publications with comprehensive bibliography of the related essays 
[47]. However, many methods to explore this potential did not lead to the convincing results, 
especially if historical indications were directly correlated to modern applications or if the 
authors concentrated on a single defined species. Recent studies in history of pharmacy pre-
sent methods and concepts to analyse historical traditions in detail, evaluate them according 
to modern scientific knowledge and link the results directly to the scientific research of the 
pharmaceutical branch disciplines like pharmacognosy, chemistry and pharmacology to lead 
to a complete drug development [48, 49, 50].  
Millennia of experience in evidence-based applications of innumerable medicinal plants used 
in all cultures wait to be analysed, explored and made available for modern therapy, be it as 
multi-compound pleiotropic preparations (herbal medical products / botanicals) or as pure 
natural products [2,4] and of course based on the modern legal frameworks including the 
Convention on Biological Diversity [8, 42] and subsequent treaties. Already Tschirch recog-
nized the value of historical traditions and the potential for discovering mixtures or substanc-
es with a potential for a wider use. Specifically, his concept of the synergistic efficacy of all 
compounds of a plant extract should be studied further in the context of understanding the 
implications for efficacy. While Tschirch did not have the methodological and instrumental 
equipment to investigate the different preparations, their respective profiles and fingerprints, 
their clinical efficacy and the necessary modifications and dosages, we can explore this wide 
and still little known field as another core competence of pharmacognosy.  
The analytical power of modern hyphenated techniques and the opportunities of DNA bar-
coding provide great opportunities for a much better understanding of complex preparations 
and give a new impetus to pharmacognostic research approaches. A key challenge will be the 
large number of local and traditional medicines used and traded in and from biodiversity rich 
countries with a long and strong tradition of using herbal medicines especially from Asian 
countries like China, Thailand and India, but also from American and African countries. It 
can be predicted with certainty that this trade will continue to increase and there will be an 
increased need for pharmacognostical-analytical tools to assess the authenticity and quality of 
these products. 
Pharmacognosy combines rich historical traditions and millennia of evidence-based 
knowledge with the expertise and skills of modern science and, therefore, is an irreplaceable 
and promising science for drug discovery and the development of modern drugs. In the future 
it may even be a new medical-pharmaceutical paradigm which could focus in multi-
compound mixtures as therapeutics in an adapted regulatory framework.   
We would like to close with some contemplative thoughts by the famous and renowned 
pharmacist and pharmacognosist Franz Christian Czygan (1934-2012). In 1984, he wondered 
whether the exploration of medicinal plants had been neglected for such a long time that the 
clock already showed five after twelve. While concentrating on smallest details, we lose the 
view for the whole and therefore so many plants and other natural sources like marine organ-
isms including their compounds on our planet have not been explored, which could offer an 
immense potential of therapeutic options. Therefore, it is our responsibility as scientists to 
preserve and investigate plants and further natural sources as a heritage and for the benefit of 
mankind [45]. 
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